- Home
- LOPE vs GH Comparison
LOPE vs GH Comparison
Compare LOPE & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOPE
- GH
- Stock Information
- Founded
- LOPE 1949
- GH 2011
- Country
- LOPE United States
- GH United States
- Employees
- LOPE N/A
- GH N/A
- Industry
- LOPE Other Consumer Services
- GH Medical Specialities
- Sector
- LOPE Real Estate
- GH Health Care
- Exchange
- LOPE Nasdaq
- GH Nasdaq
- Market Cap
- LOPE 4.9B
- GH 5.5B
- IPO Year
- LOPE 2008
- GH 2018
- Fundamental
- Price
- LOPE $196.10
- GH $41.72
- Analyst Decision
- LOPE Buy
- GH Strong Buy
- Analyst Count
- LOPE 3
- GH 21
- Target Price
- LOPE $201.00
- GH $52.81
- AVG Volume (30 Days)
- LOPE 230.2K
- GH 2.7M
- Earning Date
- LOPE 05-06-2025
- GH 04-30-2025
- Dividend Yield
- LOPE N/A
- GH N/A
- EPS Growth
- LOPE 11.24
- GH N/A
- EPS
- LOPE 7.94
- GH N/A
- Revenue
- LOPE $1,047,637,000.00
- GH $773,996,000.00
- Revenue This Year
- LOPE $7.45
- GH $19.53
- Revenue Next Year
- LOPE $6.67
- GH $21.92
- P/E Ratio
- LOPE $24.71
- GH N/A
- Revenue Growth
- LOPE 6.31
- GH 28.20
- 52 Week Low
- LOPE $130.69
- GH $18.01
- 52 Week High
- LOPE $192.18
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- LOPE 71.06
- GH 43.79
- Support Level
- LOPE $183.54
- GH $38.86
- Resistance Level
- LOPE $202.28
- GH $52.92
- Average True Range (ATR)
- LOPE 4.90
- GH 2.91
- MACD
- LOPE 2.06
- GH -0.74
- Stochastic Oscillator
- LOPE 81.91
- GH 20.34
About LOPE Grand Canyon Education Inc.
Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges both online, on the ground at its campus in Phoenix, Arizona and at four off-site classroom and laboratory sites. The Company generates all of its revenue through services agreements with its university partners.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.